BAYER AG NA O.N.
Commented by Fabian Lorenz on January 25th, 2023 | 13:54 CET
Bayer shares soon to reach triple digits? Barrick Gold and Desert Gold praised by analysts
Will Bayer be broken up, or will triple-digit share prices beckon? According to media reports, more and more investors are calling for the former. Most recently, Bluebell Capital Partners. According to the Bloomberg news agency, the British investor is calling on the DAX-listed Company to separate its Crop Science and Pharmaceuticals divisions. This could lead to a 70% increase in value for shareholders. Analysts also see considerable share price potential and believe that triple-digit prices are possible. Gold is also shining again. However, this has yet to be realized by exploration companies in particular. Experts see the chance of a revaluation at Desert Gold, for example - through takeover fantasy and drilling results. Besides B2Gold, Barrick Gold also comes into question as a buyer. The industry leader is also recommended as a buy, despite weakening Q4 results.
Read
Commented by Armin Schulz on January 9th, 2023 | 17:35 CET
BioNTech, Defence Therapeutics, Bayer - Is a Corona tsunami imminent?
At the beginning of December, things were quiet concerning Corona. The feared wave failed to materialize, and there were no new variants. On December 7, China announced a relaxation of Corona measures. Now the country is facing a gigantic Corona wave. Many European countries have already imposed mandatory testing for entry from China. Germany has now followed suit. In parallel, the Consumer Electronics Show 2023 ran from the 5th to the 8th in Las Vegas, where all kinds of companies from all over the world presented their latest technology. Chinese companies also exhibited there. Because of the multitude of infections, new deadly mutations could emerge. As a result, pharmaceutical and biotech companies are coming back into focus.
Read
Commented by André Will-Laudien on January 5th, 2023 | 06:35 CET
It is the year 2023 and COVID is back! BioNTech, Bayer, Defence Therapeutics, Morphosys - Which stocks stand up to the virus from China?
The next COVID wave is raging in China. The situation is no less dramatic today than in 2019 because until now, only vaccines produced in the country may be administered to locals in China. Before Christmas, however, the German government obtained permission to have Germans in China vaccinated with the active ingredient from BioNTech and immediately had the first doses flown out to Beijing. Yesterday, the EU discussed a joint reaction to the current conditions in China. German medical officials are calling for mandatory Europe-wide testing of all people entering the country and are warning of a new, dangerous virus mutation due to the large numbers of infections. Investors are therefore taking the vaccine experts back into focus.
Read
Commented by Fabian Lorenz on December 14th, 2022 | 12:02 CET
Bayer, BioNTech, Auxico Resources: 200% price gain possible?
With lower than expected inflation in the US, the year-end rally has picked up speed. Could the recession be off after all, or at least short-lived? This would likely boost the stock market in the coming year as well. Today we look at three stocks with potential that benefit from global trends and less from developments in Germany. In the case of Bayer, Bernstein Research has outed itself as a super bull. The global agricultural business should continue to run strong. Auxico Resources is positioning itself as a trader of rare earths and critical raw materials. Revenues are expected to jump significantly in the coming year, and analysts say the stock could triple. BioNTech could finally break out of the sideways trend it has been in since early 2022. The new combination vaccine and the cancer pipeline give hope.
Read
Commented by Fabian Lorenz on December 7th, 2022 | 10:46 CET
Bayer, BYD, TubeSolar: Stocks for the year-end rally and beyond?
Investors are currently positioning themselves for the year-end rally. To that end, today, we look at three exciting and very different stocks. BYD has become Tesla's biggest competitor. But the "honeymoon" for electric vehicles in China is coming to an end, analysts say. What is the story? Bayer has increasingly emerged from the shadow of the glyphosate issue this year. Analysts continue to see upside potential for the DAX company. Just like the new German solar hopeful TubeSolar. If the energy turnaround is to succeed, companies like this are needed. After all, the Augsburg-based company is convincing with its innovative technology and could achieve rapid sales growth in the coming years - does this also apply to the share price?
Read
Commented by André Will-Laudien on December 5th, 2022 | 12:43 CET
Attention biotech stocks: Bayer, BioNTech, Defence Therapeutics and Morphosys - These stocks look good!
After months of selling off, they are back: biotech stocks! A strong turn on the NASDAQ quickly flushed the beaten-up stocks back to the top of the hit lists. With COVID out of the spotlight, companies are returning to their long-term research lines. These have been heavily focused on cancer in recent years, and now there is even groundbreaking news on metastasis. BioNTech has thus already gained more than 40% since the October low. Morphosys, on the other hand, lost another 40% after an Alzheimer's study failed to deliver valuable results. It is worth taking another look at the sector.
Read
Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET
Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions
Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.
Read
Commented by Nico Popp on November 21st, 2022 | 12:11 CET
Biotech - Hotter than ever: Catalyst Pharmaceuticals, BioNxt Solutions, Bayer
Biotechs have been providing answers to humanity's most pressing questions for years. Innovative companies are applying advanced methods to make a medical difference. The example of BioNTech is just one success story among many. While companies in the pharmaceutical sector are finding it increasingly difficult to come up with real innovations, biotechs often put all their eggs in one basket - and win. We present two biotech hopefuls and take a look at Bayer.
Read
Commented by Juliane Zielonka on November 17th, 2022 | 13:48 CET
BioNxt Solutions, Pfizer, Bayer - Biotech and pharma stocks in focus
Pharma and biotech companies are still booming. However, large corporations like Pfizer and Bayer need help maintaining their market dominance with long-term studies and patent extensions. Pfizer, in particular, experienced the rush of speed in recent years thanks to the emergency approval of the Covid-19 vaccine. In hindsight, however, voices are growing louder about the potential long-term damage of this market cut. Multi-million dollar lawsuits may result. Positioning itself in the mental health niche, whose market size was USD 381.98 billion in 2020, is BioNxt Solutions. Their mission: to tackle depression, anxiety and PTSD with natural substances. A look at the data.
Read
Commented by André Will-Laudien on November 16th, 2022 | 11:27 CET
That hit home! Roche and Morphosys fail with Alzheimer's study, Bayer and Defence Therapeutics continue to rise strongly
It is common for biotech stocks to publish study results as well as figures several times a year. Since there are usually only expenses and few sales to report for these stocks fundamentally, analysts focus on the clinical successes in the way of a trial for the approval of new active substances. This can sometimes lead to erratic price movements. Roche and Morphosys suffered the same fate at the beginning of the week, with their share prices plummeting on the back of bad news. We take a look at a hot sector.
Read